TickerTalks
Browse all tickers →
TickerTalks›$STIM
STSTIM

Neuronetics, Inc.

Hot onWhy it's trendingX chatter spiked vs its recent normMoving on elevated volumeRecent insider buying
$STIM·$122M·Medical - Diagnostics & Research·Healthcare
$1.69-5.3%YTD+29.0%1Y-50.6%
Mentions · last 7 days
2026-07-10: 27 posts2026-07-11: 7 posts2026-07-12: 13 posts2026-07-13: 35 posts2026-07-14: 20 posts2026-07-15: 53 posts2026-07-16: 102 posts257+22%
Price updated 11m ago·X counts updated 20h ago
STSTIM
$STIMNeuronetics, Inc.
$1.69-5.34%257 posts+22%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $STIM, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Neuronetics up 33% YTD with activist Chernett at 15% — TMS depression franchise plus Greenbrook clinic network.

Neuronetics operates the NeuroStar transcranial magnetic stimulation (TMS) platform for depression treatment plus the Greenbrook TMS clinic network with 95+ locations — the largest branded Spravato support footprint. The stock is up 33% YTD as activist investor Chernett accumulates to 15%.

  • Revenue grew 8% YoY last quarter with a -26% operating margin — the top line is stabilizing but operating losses persist; the equity value depends on continued Greenbrook clinic network monetization.
  • Trades at 0.59x TTM sales with negative TTM P/E on cyclical losses — reasonable multiples for a small-cap medical-device-plus-services franchise; the $122M market cap reflects deep distress despite the strategic footprint.
  • Activist Jorey Chernett's SC 13D/A amendment (May 27) plus continued open-market accumulation to 15.17% — real activist engagement with specific demands for a comprehensive strategic review; his July 15 P-Purchase of $62K confirms continued conviction.
  • The Greenbrook 95+ clinic network as 'largest branded Spravato support footprint' is a real strategic asset — genuine differentiation that peers can't easily replicate.
  • 52-week position 26th percentile with position vs 200-day MA +7% — the tape has stabilized from the recent lows; the setup depends on continued activist engagement.

August 4 Q2 earnings is where the activist-catalyst story either extends or contracts: revenue growth held plus specific Greenbrook clinic monetization commentary is what confirms the setup; a modest print or a delayed strategic-review outcome is where the tape gives back. Real depression-treatment franchise with real activist alignment and real strategic-review optionality — the setup rewards continued activist pressure.

Agrees with X sentimentThe bullish X take on Chernett's $1.06M stake increase to 15.17%, the Greenbrook 95+ location branded Spravato support network, and the ~41% short-float framing is analytically fair. The activist-plus-short-squeeze dynamics support the fundamental case.

What to watch: Aug 4 Q2 earnings — need revenue growth held and specific Greenbrook clinic monetization commentary. A modest print or delayed strategic-review outcome is where the tape gives back.

On the calendar: 2026-08-04 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-06-03

Posters frame Neuronetics as an undercovered small cap, highlighting activist Jorey Chernett increasing his stake by $1.06M to 15.17% and reinforcing his prior demands for a comprehensive strategic review. Bulls cite the Greenbrook clinic network of 95-plus locations as the largest branded Spravato support footprint and the NeuroStar transcranial magnetic stimulation platform as a structural tailwind. Short float is noted at roughly 41%. The thin sample is uniformly constructive with no bearish content.

Read the AI verdict + X sentiment for $STIM

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Commercial medical device company selling NeuroStar TMS systems for office-based treatment-resistant depression therapy.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $STIM.

Medical - Diagnostics & Research · Healthcare

No material change from last week — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials.

What this means for $STIM

Neutral — Commercial medical device company selling NeuroStar TMS systems for office-based treatment-resistant depression therapy; the pharma R&D recovery and CDMO outsourcing demand expansion does not materially affect this business's near-term earnings.

Industry benchmark

13-name peer basket
+34.0%YTD
+67.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-28.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-19.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-15.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-165%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
48.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$-0.16$-0.17+5.9%
Q4 2025Mar 17, 2026$-0.10$-0.12+16.7%
Q3 2025Nov 4, 2025$-0.13$-0.12-8.3%
Q2 2025Aug 5, 2025$-0.15$-0.08-87.5%
Next earningsTue, Aug 4·consensus EPS $-0.11

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$34.5M+7.8%46.9%-26.1%$-0.16$-9.6M
Q4 FY25$41.8M+85.7%52.0%-12.1%$-0.10$692K
Q3 FY25$37.3M+101.3%45.9%-19.6%$-0.13$-899K
Q2 FY25$38.1M+131.7%46.6%-21.1%$-0.15$-3.8M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$161.1M$158.5M – $163.3M-$0.46-$0.47 – -$0.452
FY27$177.9M$175.0M – $180.4M-$0.34-$0.34 – -$0.332
FY28$197.8M$194.6M – $200.6M-$0.31-$0.32 – -$0.301
FY29$216.1M$212.6M – $219.1M-$0.30-$0.31 – -$0.291
FY30$237.1M$233.3M – $240.4M-$0.30-$0.31 – -$0.291

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.8.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.24%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+24.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+3.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 28.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today41.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.065-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJul 14Jorey Chernett10% owner35.0K sh$62KBuyMay 19Jorey Chernett10% owner100.0K sh$117KBuyMay 12Jorey Chernett10% owner475.0K sh$637KBuyApr 21Jorey Chernett10% owner100.0K sh$151KBuyApr 20Jorey Chernett10% owner100.0K sh$158KBuyMar 30Jorey Chernett10% owner385.4K sh$482KBuyMar 27Jorey Chernett10% owner500.0K sh$675KBuyMar 26Jorey Chernett10% owner25.0K sh$36KBuyMar 25Jorey Chernett10% owner125.0K sh$175KBuyMar 20Jorey Chernett10% owner169.5K sh$239K
1–10 of 24
+ 15 other (12 awards · 3 others) in window

See when $STIM insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 133
AI summary

Neuronetics (STIM) — Form 3 initial ownership for Cory Anderson (EVP and General Manager, Greenbrook). Anderson holds approximately 411,477 direct shares plus multiple RSU tranches. Material — unusually large direct-share holding (~411K shares) for an EVP, likely reflecting equity from the Greenbrook integration into Neuronetics.

8-KOfficer or director changeJun 238-K — Item 5.02: Officer or director change
AI summary

Delaware 001-38546 33-1051425 reported a compensatory arrangement or officer/director change: Certain Officers. (c) On June 16, 2026, the board of directors of the Company (the “Board”) promoted Cory Anderson from the position of Senior Vice President, Chief Technology Officer to the position of Executive Vice President, General Manager of Greenbrook effective July 1, 2026 (the “Anderson Promotion Date”). There is no arrangement or understanding between Mr. Anderson and any other person pu.

8-KShareholder voteMay 298-K — Item 5.07: Shareholder vote
AI summary

Neuronetics, Inc. held its 2026 Annual Meeting of Stockholders on May 28, 2026, with approximately 80.41% of eligible shares represented. Stockholders voted on director elections, a non-binding say-on-pay advisory vote, and auditor ratification. Final results for each proposal are disclosed. This is a routine annual meeting governance filing with no material corporate actions.

SC 13D/AActivist amendmentMay 27SC 13D/A
AI summary

Individual investor reporting person Chernett filed Amendment No. 2 to his Schedule 13D for Neuronetics, Inc. (STIM), reporting beneficial ownership of 10,553,988 shares (15.17% of the 69,587,840 shares outstanding as of May 1, 2026), purchased with personal funds for an aggregate price of approximately $20,619,936. The amendment updates ownership or intent since the original March 31, 2026 13D filing. At 15.17%, Chernett is the largest known individual holder of Neuronetics and the scale of his position warrants monitoring as a potential activist or strategic catalyst in the TMS therapy device company.

8-KOfficer or director changeMay 228-K — Item 5.02: Officer or director change
AI summary

Neuronetics, Inc. disclosed that its Interim Principal Financial and Accounting Officer Francis X. Brown III operates pursuant to an amended and restated consulting agreement effective May 5, 2026, under which his consulting fees were updated. The amendment formalizes and adjusts the compensation arrangements for the interim PAO role. This is an administrative update to an already-disclosed leadership transition; Neuronetics continues to search for a permanent CFO while Brown fills the interim role.

3New insider — initial holdingsMay 133
AI summary

Francis X. Brown III filed an initial Form 3 for Neuronetics, Inc. (STIM) as of May 5, 2026, upon becoming the company's Interim Principal Financial and Accounting Officer — as previously disclosed in the companion 8-K. This is a routine Section 16 compliance filing accompanying the announced interim CFO appointment.

8-KPress release / Reg FDMay 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Neuronetics (STIM) reported Q1 2026 financial results and disclosed related investor communications on May 5, 2026. Items 2.02 and 7.01 cover the earnings release and Regulation FD investor call details. Neuronetics makes NeuroStar, a transcranial magnetic stimulation (TMS) system for treating major depressive disorder.

SC 13D/AActivist amendmentApr 8SC 13D/A
AI summary

An activist investor (Chernett or affiliated entity) filed an amended Schedule 13D/A for Neuronetics (STIM) on April 6, 2026, attaching a letter to the Board of Directors calling for a comprehensive strategic review, including a potential sale of the TMS (transcranial magnetic stimulation) business segment. The filing intensifies pressure on Neuronetics management amid the CEO's concurrent retirement and restructuring plan. This is a significant activist catalyst.

+ 22 other (5 8-Ks · 3 13Gs · 2 proxys · 2 3s) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026globenewswire.com·11d agoNeuronetics Appoints Robert Greene as Senior Vice President Salesglobenewswire.com·45d agoNeuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026globenewswire.com·45d agoNeuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatmentglobenewswire.com·64d agoNeuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcriptseekingalpha.com·73d ago

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMO$DHR$IQV$A$ILMN$NTRA$TWST$PSNL
Voices on X · top 5 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport